COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE
Edouard Louis 1
Pravin Kamble 2
Dirk Lindner 3
Christian Agboton
1 CHU Liège and Liège University, Liège, Belgium
2 Takeda Pharmaceuticals Inc., Marlborough, United States
3 Takeda Pharmaceuticals, Zurich, Switzerland
Session
IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]